Categories Earnings, Health Care
Earnings Summary: Gilead Sciences reports higher Q2 revenue and profit
Gilead Sciences, Inc. (NASDAQ: GILD), a leading research-based biopharmaceutical company, has reported an increase in revenues and adjusted earnings for the second quarter of 2024.
- Second-quarter revenue increased 5% from last year to $7.0 billion, aided by higher product sales in HIV, Liver Disease, and Oncology
- Earnings, on a per-share basis, were $1.29 in the second quarter, compared to $0.83 in the same period in 2023
- Adjusted earnings per share increased to $2.01 in the June quarter from $1.34 in the prior-year period
- Net income attributable to Gilead advanced to $1.61 billion in Q2 from $1.05 billion in the year-ago quarter
- As of June 30, 2024, the company had $2.8 billion of cash, cash equivalents, and marketable debt securities, vs. $8.4 billion a year earlier
- During the quarter, Gilead generated $1.3 billion in operating cash flow; it paid dividends of $972 million and repurchased $100 million of common stock
Listen to the conference calls as they happen. Don't miss a beat! With AlphaStreet Intelligence, you can listen to live calls and interviews as they happen, so you never have to worry about missing out on important information.
Most Popular
Kroger’s Q3 report likely to reflect consumer caution amid macro headwinds
The Kroger Co. (NYSE: KR) is preparing to report third-quarter results this week while navigating a challenging market environment. In the first half, the grocery chain's performance was not very
Estee Lauder (EL): A look at the challenges weighing down this beauty giant
Shares of The Estée Lauder Companies Inc. (NYSE: EL) rose over 2% on Monday. The stock has dropped 19% over the past three months. The beauty company had a disappointing
Hormel Foods (HRL) to report Q4 2024 earnings results, a look at what to expect
Shares of Hormel Foods Corporation (NYSE: HRL) rose over 1% on Friday. The stock has gained over 5% in the past one month. The branded food company is slated to
